| Outcome | Findings in words | Findings in numbers | Quality of evidence |
|---|
| Global state |
|---|
No marked improvement (CGI)
Follow-up: 3 to 12 months | Penfluridol does not clearly change the chance of experiencing 'no marked improvement' when compared with receiving typical antipsychotic drugs. These findings are based on data of low quality. | RR 0.92 (0.68 to 1.24) | Low |
Global state - needing additional antipsychotic
Follow-up: less than 3 months | There is no clear difference between people given penfluridol and those receiving typical antipsychotics. These findings are based on data of low quality. | RR 1.35 (0.90 to 2.01) | Low |
| Mental state |
|---|
Average score (BPRS)
Follow-up: 3 to 12 months | On average, people receiving penfluridol scored higher than people treated with typical antipsychotics (oral) but there was no clear difference between the groups and this finding is based on data of low quality. The meaning of this in day-to-day care is unclear. | MD 1.24 higher (4.4 lower to 6.88 higher) | Low |
| Adverse events |
|---|
Needing antiparkinsonism medication
Follow-up: less than 3 months | There is no clear difference between people given penfluridol and those receiving typical antipsychotics (oral). These findings are based on data of low quality. | RR 1.09 (0.61 to 1.97) | Low |
Insomnia
Follow-up: less than 3 months | There is no clear difference between people given penfluridol and those receiving typical antipsychotics (oral). These findings are based on data of low quality. | RR 1.07 (0.51 to 2.24) | Low |
| No study reported any data on outcomes such asquality of life and information relating to time in services | | |
N
Y (what is this?) (verify)